Sign Up Today and Learn More About Personalis Stock
Invest in or calculate the value of your shares in Personalis or other pre-IPO companies through EquityZen's platform.
Personalis Stock
Contract research organization and genome-scale diagnostics services company
About Personalis Stock
Founded
2011
Headquarters
Menlo Park, CA, US
Total Funding
75.0M
Industries
Science and Engineering, Health Care, Biotechnology
Personalis combines expertise both in the technology of sequencing and in interpretation, with an extensive history of peer reviewed publication and commercial success. Broad adoption of medical genome interpretation will require accuracy befitting regulatory approval, both in variant detection and interpretation. More than half of the founding team are MDs, and this reflects the company's commitment to serious medically-focused results, at quality standards eventually suitable for regulatory approval and insurance reimbursement. The team includes experienced PhD scientists, who know that the research community also cares deeply about accuracy, thoroughly substantiated and peer-reviewed. Personalis has exclusively licensed key intellectual property originating in the labs of the founders. Lastly, the Personalis team includes business people with decades of experience in genetic analysis, who know that the democratization of genome sequencing will also require high-quality customer support for interpretation, lab by lab, genome after genome.
Personalis Management
Leadership team at Personalis
Chief Executive Officer
John West
Vice President Finance and Administration
Carol J. Tillis
Join now and verify your accreditation status to gain access to:
- Personalis current valuation
- Personalis stock price
- Available deals in Personalis and all other companies
- Deal offering documents
- EquityZen's proprietary data and insights, including
- Cap tables, which include funding history by Share Class and Liquidity Preferences
- Company Highlights
- Business Model
- Risk Factors
How to invest in Personalis stock?
Accredited investors can buy pre-IPO stock in companies like Personalis through EquityZen funds. These investments are made available by existing Personalis shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Personalis stock?
Shareholders can sell their Personalis stock through EquityZen's private company marketplace. EquityZen's network includes over 320K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 42K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
